Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS
May 8, 2017 6:54 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.42, in-line with the analyst estimate of $1.42. Revenue for the quarter came in at $76.8 million versus the consensus estimate of $70.37 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More